235 filings
Page 5 of 12
8-K
oglstpxfq yu2l6v
27 Mar 20
Other Events
12:53pm
8-K
xcaprk0wnis8
12 Mar 20
Other Events
8:47am
8-K
wlwc1vxsxujdbtqe0vo
11 Mar 20
Regulation FD Disclosure
4:05pm
8-K
o5twyybohdvbwev4fodl
20 Feb 20
Other Events
9:12am
8-K
tr7smv djq55gus4k
12 Feb 20
Entry into a Material Definitive Agreement
4:55pm
8-K
jc99i2l
12 Feb 20
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple
4:24pm
8-K
esp9ih8
7 Feb 20
Regulation FD Disclosure
4:46pm
8-K
hr4c5399
28 Jan 20
Other Events
4:24pm
8-K
5szqe8
9 Jan 20
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
12:00am
8-K
m15s2 y4a7m7z10
6 Jan 20
Hepion Pharmaceuticals Announces Publication inExpert Opinion on Investigational Drugs
4:23pm
8-K
maiqgiptbkzc8
11 Dec 19
Other Events
1:26pm
8-K
33l809
4 Dec 19
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
12:00am
8-K
8uwlf9 r5g
3 Dec 19
Regulation FD Disclosure
4:15pm
8-K
ssoe3cy nmqx
20 Nov 19
Other Events
9:27pm
8-K
ulmpn
8 Nov 19
Hepion Pharmaceuticals to Present at The Liver MeetingÒ 2019
12:00am
8-K
tj0ykeb21q6zbaw71wx
7 Nov 19
Other Events
12:55pm
8-K
jnp81iy0 6aokw9km
23 Oct 19
Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
4:29pm
8-K
drz 63036
16 Oct 19
Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431’s Potential as a Treatment for Chronic Liver Diseases
4:54pm
8-K
km6ocopvbb44 rdl
10 Oct 19
World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
11:33am
8-K
3k4mv6yw2
8 Oct 19
Departure of Directors or Certain Officers
4:15pm